Cosentyx Mechanism and Vaccine Impact
Cosentyx (secukinumab) is an IL-17 inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. It suppresses parts of the immune system, raising infection risks and potentially weakening vaccine responses, especially live vaccines.[1]
Live Vaccines: Avoid During Treatment
Novartis, Cosentyx's manufacturer, contraindicates live vaccines (e.g., MMR, varicella, oral polio, yellow fever) while on treatment and for several weeks after stopping. Live vaccines can replicate in an immunocompromised person, causing disease. Wait at least 4-6 weeks post-discontinuation before live vaccines, per product labeling and CDC guidelines.[1][2]
Inactivated Vaccines: Safe and Recommended
Inactivated or subunit vaccines (e.g., flu shot, Tdap, COVID-19 mRNA vaccines like Pfizer/Moderna, pneumococcal) are generally safe with Cosentyx. Studies show they produce immune responses, though sometimes reduced:
- COVID-19 vaccines: Antibody levels lower but still protective; boosters advised.[3]
- Influenza: Similar reduced response; annual shots encouraged.[4]
Timing: Administer before starting Cosentyx if possible, or anytime during treatment. No mandatory gaps needed.
Pneumococcal and Shingrix Timing
PCV13/20 (pneumococcal) and Shingrix (shingles, recombinant) work well on Cosentyx. Vaccinate proactively, as patients on biologics face higher pneumonia/shingles risks. Complete series before therapy if feasible.[2][5]
What Happens with Poor Timing?
No evidence of harm from inactivated vaccines during Cosentyx, but live vaccines risk active infection. Monitor for reduced efficacy—test antibody titers post-vaccination if high-risk (e.g., travel). Delaying non-urgent vaccines until off Cosentyx restores stronger responses.[3]
Doctor Guidance and Real-World Practice
Rheumatologists/dermatologists coordinate via shared plans. CDC's general rule for biologics: Prioritize inactivated vaccines; avoid live ones. Consult your provider for personalized timing, especially pre-surgery or travel.[2]
[1]: Novartis Cosentyx Prescribing Information
[2]: CDC Vaccine Guidelines for Immunocompromised Adults
[3]: Study on COVID-19 vaccine response in IL-17 inhibitors
[4]: Influenza vaccine efficacy in psoriasis biologics
[5]: Shingrix in autoimmune disease